Skip to main content

Table 1 Demographic and Clinical Characteristics of Patients at Baseline

From: Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer

Characteristic No. of patients (%) Univariate analysisaP value
Age (years)
 Median (Range) 56.5 (34–81)  
  ≤ 56: >  56 63 (50): 63 (50) .293
Gender
 Male: Female 121 (96.0): 5 (4.0) .077
Body mass index
 Median (Range) 21.4 (15.5–30.0)  
  ≤ 21.4: >  21.4 64 (50.8): 62 (49.2) .721
Body surface area
 Median (Range) 1.65 (1.3–2.1)  
  ≤ 1.65: >  1.65 66 (52.4): 60 (47.6) .784
Eastern Cooperative Oncology Group performance status
 0: 1: 2: 3 12 (9.5): 98 (77.8): 15 (11.9): 1 (0.8) .539
Stage
 I: II: III 2 (1.6): 10 (7.9): 114 (90.5) .600
Tumor location
 U: M: L 51 (40.5): 30 (23.8): 20 (15.9) .001
 U + M 9 (7.1)  
 U + M + L 1 (0.8)  
 M + L 15 (11.9)  
Histology
 Squamous cell carcinoma 121 (96.0) .508
 Adenocarcinoma 3 (2.4)  
 Poorly differentiated carcinoma 2 (1.6)  
Smoking
 Yes: No 114 (90.5): 12 (9.5) .350
Alcohol
 Yes: No 115 (91.3): 11 (8.7) .094
Hypertension
 Yes: No 25 (19.8): 101 (80.2) .418
Diabetes
 Yes: No 15 (11.9): 111 (88.1) .582
Cardiovascular disease
 Yes: No 7 (5.6): 119 (94.4) .097
Radiation dose (Gray)
 Median (range) 61.2 (50–66.6)  
  ≤ 60: >  60 52 (41.3): 74 (58.7) .238
Chemotherapy regimen
 Fluoropyrimidine-based 118 (93.7) .900
 Taxane-based 4 (3.2)  
 Others 4 (3.2)  
  1. Abbreviations: L lower thoracic esophagus, M middle thoracic esophagus, U upper thoracic esophagus
  2. aUnivariate analysis of patients’ characteristics associated with pericardial effusion